Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients

Antiviral Therapy

Volumn 13, Issue 4, 2008, Pages 607-611

  Maynard, Marianne ^a,b,c   Pradat, Pierre ^a,b,c   Gagnieu, Marie Claude ^d   Souvignet, Claude ^a,c   Trepo, Christian ^a,b,c  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMA; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 47649106599     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355:2444-2451.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
4. Jacobson IM, Brown RS, Jr., Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46:971-981.
5. Smith J, Han SH. "True" weight-based dosing versus "flat" dosing of ribavirin: will the WIN-R please come forward? Hepatology 2007; 46:953-956.
6. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22:555-565.
7. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003; 47:124-129.
8. Maynard M, Gagnieu MC, Pradat P, Bailly F, Trepo C. Relevance of ribavirin plasma concentration for the prediction of treatment response. EASL 2005, Paris. J Hepatol 2005; 42 Suppl 2:224.
9. Homma M, Jayewardene AL, Gambertoglio J, Aweeka F. High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes. Antimicrob Agents Chemother 1999; 43:2716-2719.
10. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19 Suppl 1:17-24.
11. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006; 62:699-709.
12. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131:1040-1048.
13. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
14. Enomoto M, Nishiguchi S, Kohmoto M, et al. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. J Viral Hepat 2004; 11:448-454.
15. Nunez M, Camino N, Ramos B, et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther 2005; 10:657-662.
16. Ramos B, Nunez M, Rendon A, et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. J Viral Hepat 2007; 14:387-391.
17. Rendon AL, Nunez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005; 39:401-405.
18. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46:1548-1563.
19. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41:275-279.
20. Arase Y, Ikeda K, Tsubota A, et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005; 48:138-144.
21. McHutchison JG, Manns MP, Brown RS, Jr., Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102:880-889.
22. Treluyer JM. Intérêt de la mesure des concentrations plasmatiques des antirétroviraux dans la prise en charge des patients infectés par le virus de l'immunodéficience humaine [The promise of therapeutic drug monitoring in HIV infection]. Ann Med Interne (Paris) 2000; 151:291-296. French.